Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vivo Topoisomerase I Inhibition Attenuates the Expression of Hypoxia-Inducible Factor 1α Target Genes and Decreases Tumor Angiogenesis

19 Oct 2011

Abstract excerpt

Topoisomerase I is a privileged target for widely used anticancer agents such as irinotecan. Although these drugs are classically considered to be DNA-damaging agents, increasing evidence suggests that they might also influence the tumor environment. This study evaluates in vivo cellular and molecular modifications induced by irinotecan, a topoisomerase I-directed agent, in patient-derived colon tumors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Cancer therapeutics and mechanisms
Share to Hepatocellular Carcinoma Treatment and Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22033674
DOI: 10.2119/molmed.2011.00120

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vivo Topoisomerase I Inhibition Attenuates the Expression of Hypoxia-Inducible Factor 1α Target Genes and Decreases Tumor AngiogenesisPMID 22033674Read ↗

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targetsSemantic proximity Read ↗

Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase InhibitorsSemantic proximity Read ↗

Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecanSemantic proximity Read ↗

Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancerSemantic proximity Read ↗

Increased topoisomerase IIα expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosisSemantic proximity Read ↗

A novel camptothecin derivative, ZBH-01, exhibits superior antitumor efficacy than irinotecan by regulating the cell cycleSemantic proximity Read ↗

The Natural Inhibitor of DNA Topoisomerase I, Camptothecin, Modulates HIF-1α Activity by Changing miR Expression Patterns in Human Cancer CellsSemantic proximity Read ↗

DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic TargetsSemantic proximity Read ↗

Clinical and Cellular Roles for TDP1 and TOP1 in Modulating Colorectal Cancer Response to IrinotecanSemantic proximity Read ↗

Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitorsSemantic proximity Read ↗

Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.Semantic proximity Read ↗

New Topoisomerase I mutations are associated with resistance to camptothecin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.